BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed EIKN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:200fa4babaf10dbe4ab1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:EIKN P2 readout (est.): A Phase 2 Study of EIK1001 in Combo With Pe
 mbrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
DESCRIPTION:A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chem
 otherapy in Patients With Stage 4 NSCLC\nNCT06246110 | PHASE2 | ACTIVE_NOT
 _RECRUITING | sponsor: Eikon Therapeutics\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nDate precision: month (show
 n on the first day)\nTicker EIKN (confidence 0.9)\nSource: https://clinica
 ltrials.gov/study/NCT06246110\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06246110
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
